Study promising: Joint venture to target dry AMD treatment

St. Louis, MO-TLC Vision Corp. has made an equity investment in Vascular Sciences Corp. to establish OccuLogix, a 50/50 joint venture to commercialize Vascular Sciences' Rheopheresis blood filtration process for treating age-related macular degeneration (AMD).

Related Videos

Related Content

Advertisement

March 21st 2025

Floppy iris syndrome risk: Study finds women more susceptible, key drugs identified

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 21st 2025

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 20th 2025

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

March 20th 2025

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries

Related Content

Advertisement

March 21st 2025

Floppy iris syndrome risk: Study finds women more susceptible, key drugs identified

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

March 21st 2025

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

March 20th 2025

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

March 20th 2025

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries